PDS Biotech aims to advance and expand its proprietary pipeline programs independently or in collaboration with renowned research institutions and pharmaceutical companies.

Key commercial partners:


Strategic Research Collaborations with:

NCI Stacked COLOR nih nih niaid mayo

PDS Biotech is dedicated to maximizing the full potential of the Versamune® and combination PDS01ADC and Versamune® platforms in oncology and the Infectimune® platform in infectious diseases.

Versamune® and Versamune® plus PDS01ADC are proprietary T cell activating platform technologies which induce a strong immune response in combination with tailored antigens to fight cancer.

Infectimune® is a proprietary T cell immune activating platform technology designed to train the immune system to better protect against infectious diseases.

We are open to strategic partnerships which reflect the value-creating potential of our T cell activating platforms to provide performance-related downstream revenues, while preserving future growth opportunities for PDS Biotech.

Please contact our Business Development and Licensing Team

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up


This website use cookies to facilitate the use of the website, improve its performance and security, personalize the proposed content.